|Intravenous and oral antibiotics are not always effective for lung infections due to limited drug exposure at the infection site and bacterial resistance.
Researchers at Purdue University have developed a novel combination therapy of polymyxins for treating bacterial lung infections. Polymyxins have often been used as the last-line resort for infections caused by multi-drug resistant Gram-negative ‘superbugs’; but Inhaled polymyxins can cause toxicity in the lungs. The novel formulation developed by Purdue researchers creates a powerful therapeutic option with better antibacterial killing and much-reduced toxicity than the polymyxins alone. The Purdue dry powder formulation shows promise as an inhaled therapy, with satisfactory stability and high aerosolization performance. This innovative inhalation formulation promises a life-saving option for patients suffering from bacterial lung infections, including people infected by multidrug-resistant Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacterales.
-Decreased drug resistance
Inhalable Nanocomposite Microparticles with Enhanced Dissolution and Superior Aerosol Performance
Mol. Pharmaceutics, Published online July 24, 2020
Mar 5, 2021
Mar 11, 2020
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906
Phone: (765) 588-3475
Fax: (765) 463-3486